Herbal NF-κB Inhibitors Sensitize Rituximab-Resistant B Lymphoma Cells to Complement-Mediated Cytolysis

BACKGROUND: Drug resistance remains a serious challenge to rituximab therapy in B-NHL (B cell non-Hodgkin’s lymphoma). CDC (complement-dependent cytotoxicity) has been proposed as a major antitumor mechanism of rituximab, and direct abrogation of CD59 function partially restores rituximab sensitivit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ge, Xiaowen, Du, Yiqun, Chen, Jianfeng, Zhu, Na, Yao, Jiamei, Zhang, Xin, Wang, Na, Sun, Yujing, Gao, Feng, Hu, Weiguo, Hou, Yingyong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692258/
https://www.ncbi.nlm.nih.gov/pubmed/34956875
http://dx.doi.org/10.3389/fonc.2021.751904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8692258/
https://www.ncbi.nlm.nih.gov/pubmed/34956875
http://dx.doi.org/10.3389/fonc.2021.751904

Ejemplares similares